-transparent.png){kind=logo}
In order to evaluate the bioavailability of four different brands of phenytoin (diphenylhydantoin, DPH) tablets single doses of 600 mg DPH in acid form were given to six volunteers in a cross-over study. A micronized DPH-acid suspension was used as the reference standard. Significant differences between various products were found. The areas under the serum DPH concentration-time curves (AUC) were 26, 59, 68 and 90 per cent of the AUC of the DPH suspension. The peak serum DPH concentrations using the different tablets were 24, 54, 55 and 80 per cent of the peak value of the DPH suspension. It is likely that the differences in bioavailability of the DPH tablets are of clinical significance.
P J Pentikäinen, and
P J Neuvonen, and
S M Elfving
January 1981,
Biopharmaceutics & drug disposition,
P J Pentikäinen, and
P J Neuvonen, and
S M Elfving
January 1985,
African journal of medicine and medical sciences,
P J Pentikäinen, and
P J Neuvonen, and
S M Elfving
March 1982,
British journal of clinical pharmacology,
P J Pentikäinen, and
P J Neuvonen, and
S M Elfving
January 1978,
Neurologia i neurochirurgia polska,
P J Pentikäinen, and
P J Neuvonen, and
S M Elfving
January 1980,
Die Pharmazie,
P J Pentikäinen, and
P J Neuvonen, and
S M Elfving
October 1986,
Il Farmaco; edizione pratica,
P J Pentikäinen, and
P J Neuvonen, and
S M Elfving
July 1979,
British journal of clinical pharmacology,
P J Pentikäinen, and
P J Neuvonen, and
S M Elfving
August 1980,
Die Pharmazie,
P J Pentikäinen, and
P J Neuvonen, and
S M Elfving
October 1990,
Pharmaceutisch weekblad. Scientific edition,
P J Pentikäinen, and
P J Neuvonen, and
S M Elfving
October 1988,
International journal of clinical pharmacology, therapy, and toxicology,
